A double-blinded, randomised, three-period crossover euglycaemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of BC222 human insulin, human insulin (Huminsulin Normal) and insulin lispro (Humalog) in subjects with type 1 diabetes

Trial Profile

A double-blinded, randomised, three-period crossover euglycaemic clamp trial investigating the pharmacokinetics, glucodynamics and safety of BC222 human insulin, human insulin (Huminsulin Normal) and insulin lispro (Humalog) in subjects with type 1 diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jun 2015

At a glance

  • Drugs Insulin (Primary) ; Insulin lispro
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Adocia
  • Most Recent Events

    • 17 Feb 2015 Last checked against the European Clinical Trials Database record.
    • 05 Feb 2015 Results published in the Adocia Media Release.
    • 05 Feb 2015 Primary endpoint has been met as reported in an Adocia media release. (Increase of recombinant human insulin bioavailability during the first hour for HinsBet as compared to Humulin. AUCIns(0-1h))
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top